Beranda › Kolitis Ulseratif › Maryland
Uji klinis Kolitis Ulseratif di Maryland
13 studi untuk Kolitis Ulseratif mencari peserta di lokasi di Maryland.
Kota di Maryland
Teks studi resmi (Bahasa Inggris)
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
- National Institutes of Health Clinical Center, Bethesda
Menerima pesertaStudi observasional
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07619547A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Capital Digestive Care, Chevy Chase
- Woodholme Gastroenterology, Glen Burnie
Menerima pesertaFase 4
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06581328A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- Site 011, Glen Burnie
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07012395Immune Regulation in Ulcerative Colitis or Crohn s Disease
- National Institutes of Health Clinical Center, Bethesda
Menerima pesertaStudi observasionalSukarelawan sehat diterima
1 Day – 75 Years · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT00001184A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- Chevy Chase Clinical Research, Chevy Chase
- Woodholme Gastroenterology Associates, Glen Burnie
Menerima pesertaFase 3
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07196748Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Capital Digestive Care - Chevy Chase, Chevy Chase
Menerima pesertaFase 3
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06937086Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT03816345A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- Capital Digestive Care - MGG Group - Chevy Chase Clinical Research, Chevy Chase
Menerima pesertaFase 4
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06095128An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Mercy Medical Center, Baltimore - Site Number: 8400117, Baltimore
- Mid-Atlantic GI Research, LLC - Site Number: 8400106, Greenbelt
Menerima pesertaFase 3
Usia 16 hingga 80 · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07184996Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Mercy Medical Center, Baltimore
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT07237516An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
- MGG Group Co., Inc., Chevy Chase Clinical Research, Chevy Chase
- Woodholme Gastroenterology Associates PA, Glen Burnie
Menerima pesertaStudi observasional
Usia 18 hingga 64 · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT06398626A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- Woodholme Gastroenterology Associates, Glen Burnie
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT06764615Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- Capital Digestive Care, Chevy Chase
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Mei 2025 · NCT06750731Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.